ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2057

Analysis of the Adherence to the Monitoring of Glucocorticoid Eye Toxicity and of the Prevalence of Cataracts and Glaucoma Among Patients with Systemic Lupus Erythematosus

Linda Carli1, Chiari Tani1, Francesca Querci2, Alessandra Della Rossa1, Sabrina Vagnani3, Anna d'Ascanio4, Rossella Neri5, Antonio Tavoni6, Stefano Bombardieri3 and Marta Mosca1, 1Internal Medicine, Rheumatology Unit, Department of Internal Medicine, University of Pisa, PISA, Italy, 2Rheumatology Unit, University of Pisa, Pisa, Italy, 3Department of Internal Medicine, Rheumatology Unit, Department of Internal Medicine, University of Pisa, PISA, Italy, 4Department of Internal Medicine, University of Pisa, Rheumatology Unit, Department of Internal Medicine, University of Pisa, PISA, Italy, 5University of Pisa, Rheumatology Unit, Pisa, Italy, 6Dept of Internal Medicine, Immunoallergology Unit, Department of Internal Meicine, University of Pisa, PISA, Italy

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: glucocorticoids, Quality of care and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Quality Measures and Innovations in Practice Management and Care Delivery

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Cataracts and glaucoma are among the main causes of impaired visual acuity and have a prevalence respectively of 9-17%  and 1-2% among subjects older than 70 years. Chronic glucocorticoid (GC) therapy is associated with an increased risk of developing cataracts and glaucoma and recommendations have been developed for monitoring these side effects in patients with rheumatic diseases.

The aim of this study was to assess the adherence to the existing recommendations for monitoring eye toxicity of chronic GC therapy and the prevalence of cataracts and glaucoma among systemic lupus erythematosus (SLE) patients followed at our Unit.

Methods: Retrospective analysis of clinical charts to evaluate epidemiological data (disease duration, age at last assessment), cumulative and mean daily dose of GC and administration of GC pulses, number and frequency of eye assessment during follow up. Presence/absence of cataracts and glaucoma as reported in the last available eye assessment.

Results: One hundred and seventy charts were examined, 34 (20%) of these (mean follow up 83.6±66.5; mean age 42,5±14,8 years) never underwent an eye assessment. The remaining 136 (mean follow up 152,5±99,8 months, age 45,4±12,5 years), underwent an eye assessment on average with an interval of 75±61,7 months. However, only 45 (33%) had received an evaluation during the previous 12 months. All these 170 patients were taking chronic CG therapy at a mean daily dose of 5,4±2.4 mg prednisone (PDN), and a mean cumulative dose of  27.6±20.5 gms. Out of the 136 patients with at least one eye assessment (mean PDN 5.5±2.4 mg, mean cumulative dose 29.8±21.5 gms), cataracts were observed in 39 patients (29%) and glaucoma in 4 patients (3%). Cataracts were diagnosed at a mean age of 46,5±10 years; the development of cataracts was associated with age, disease duration and cumulative GC dose (cataracts vs not cataracts: mean cumulative PDN dose 32,8 vs 20,4 gms; p<0,0001). Glaucoma was diagnosed at a mean age of 40,5±16 years; due to the small number of patients no correlations were made.

Conclusion: Although 80% of patients have at least one eye assessment, the adherence to recommendations is suboptimal as only 33% of patients underwent an eye assessment over the previous 12 months. As expected the prevalence of cataracts and glaucoma is higher than in the general population and these conditions occur early in the life of SLE patients. As not all patients have a recent eye evaluation our data could underestimate the real incidence of these two potentially severe conditions. An association between GC and cataracts is confirmed. These data reinforce the need to improve adherence to recommendations to eye monitoring among SLE patients under chronic therapy with GC.


Disclosure:

L. Carli,
None;

C. Tani,
None;

F. Querci,
None;

A. Della Rossa,
None;

S. Vagnani,
None;

A. d’Ascanio,
None;

R. Neri,
None;

A. Tavoni,
None;

S. Bombardieri,
None;

M. Mosca,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-the-adherence-to-the-monitoring-of-glucocorticoid-eye-toxicity-and-of-the-prevalence-of-cataracts-and-glaucoma-among-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology